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Abstract The β2 adrenergic receptor (β2-AR) has become a
model system for studying the ligand recognition process and
mechanism of the G protein coupled receptors activation. In
the present study stereoisomers of fenoterol and some of its
derivatives (N =94 molecules) were used as molecular probes
to identify differences in stereo-recognition interactions be-
tween β2-AR and structurally similar agonists. The present
study aimed at determining the 3D molecular models of the
fenoterol derivative-β2-AR complexes. Molecular models of
β2-AR have been developed by using the crystal structure of
the human β2-AR T4 lysozyme fusion protein with bound
(S )-carazolol (PDB ID: 2RH1) and more recently reported
structure of a nanobody-stabilized active state of the β2-AR
with the bound full agonist BI-167107 (PDB ID: 3P0G). The
docking procedure allowed us to study the similarities and
differences in the recognition binding site(s) for tested ligands.
The agonist molecules occupied the same binding region,
between TM III, TM V, TM VI and TM VII. The residues
identified by us during docking procedure (Ser203, Ser207,
Asp113, Lys305, Asn312, Tyr308, Asp192) were experimen-
tally indicated in functional and biophysical studies as being
very important for the agonist-receptor interactions. More-
over, the additional space, an extension of the orthosteric
pocket, was identified and described. Furthermore, the molec-
ular dynamics simulations were used to study the molecular
mechanism of interaction between ligands ((R ,R’ )- and
(S ,S’)-fenoterol) and β2-AR. Our research offers new insights
into the ligand stereoselective interaction with one of the most
important GPCR member. This study may also facilitate the
design of improved selective medications, which can be used
to treat, prevent and control heart failure symptoms.
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Introduction
Fenoterol (compound 1 , Table 1) is a selective full agonist of
the β2-adrenergic receptor (β2-AR). The preliminary studies
showed that stereoisomers of the fenoterol (Fig. 1) differ
significantly in their effect on the adrenergic system [1].
Several years ago, adopting the concept of selective optimi-
zation of side activities (the SOSA approach) [2] a medicinal
chemistry project was initiated for development of β2-AR
selective agonist based on the template of compound 1 which,
combined with selective β1-AR antagonist, could be used for
the treatment of specific cardiovascular condition, namely,
congestive heart failure [3]. During the course of this research
more than 90 compounds were designed and synthesized with
various modification at the aminoalkyl tail of the fenoterol
molecule and different stereochemical configurations [1, 4–6].
These compounds, presented in Table 1, show highly diverse
binding affinities (pKi exp.) and functional activities toward
β2-AR, depending on the constitution and stereoconfiguration
of their molecules. Generally, among the different structural
analogs of 1, (R ,R’)-isomers are the most active and (S ,S’ )-
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isomers are the least active while derivatives in (R ,S’)- and
(S ,R’ )- configurations show moderate activities. Apart from
the study focused on the stereoselectivity, the influence of the
R1 and R2 substituents (Fig. 1) on the ligand-receptor interac-
tion was investigated. This also showed the results demon-
strated that the most active among fenoterol derivatives are
(R ,R’ )-isomers of such compounds as: 1, 2, 5, and 54, al-
though their relative affinity/activity measures varied signifi-
cantly depending on the assay used [1, 4]. In our previous
computational studies, the ligand–receptor interactions were
modeled using the 3D-QSAR approach. The CoMFA
(comparative molecular field analysis) models achieved very
good statistics (for details see ref [4]) and, thus, were further
used to design a series of new molecules and to predict their
pKi values in silico [1, 4]. Detailed experimental characteri-
zation of these newly designed compounds, revealed that one
of these compounds, (R ,R’ )-54 was one of the most β2
selective agonists ever reported with its selectivity ratio Ki
(β1-AR)/Ki(β2-AR) = 573 [4].
In the current study we use the molecular modeling ap-
proach based on the knowledge of the molecular structure of
the β2 adrenergic receptor. The target, β2-AR, belongs to the
Table 1 The MolDock score values obtained during docking of fenoterol stereoisomers and its derivatives to In_β2-AR and Ac_β2-AR






Score (kJ mol-1) 
Ac-β2-AR 
pKi exp. 
1. - CH3 
(R,R’)–1 -129.173 -133.699 6.46 
(R,S’)–1 -128.276 -134.649 5.43 
(S,R’)–1 -132.288 -136.294 4.99 
(S,S’)–1 -120.176 -134.607 4.56 
2. - CH3 
(R,R’)–2 -131.594 -143.97 6.32 
(R,S’)–2 -132.526 -136.982 5.71 
(S,R’)–2 -132.513 -145.924 5.28 
(S,S’)–2 -132.231 -139.689 4.80 
3. - CH3 
(R,R’)–3 -127.714 -133.919 5.53 
(R,S’)–3 -126.501 -131.835 5.10 
(S,R’)–3 -126.183 -137.152 4.64 
(S,S’)–3 -126.462 -129.941 4.54 
4. - CH3 
(R,R’)–4 -130.977 -136.893 5.73 
(R,S’)–4 -121.027 -136.285 5.22 
(S,R’)–4 -127.636 -135.894 4.51 
(S,S’)–4 -128.623 -135.302 4.54 
5. - CH3 
(R,R’)–5 -139.396 -146.715 6.62 
(R,S’)–5 -136.452 -141.921 6.47 
(S,R’)–5 -133.855 -151.305 5.75 
(S,S’)–5 -135.057 -144.819 5.60 
6. - CH3 
(R,R’)–6 -116.68 -134.419 5.03 
(R,S’)–6 -114.518 -129.026 4.50 
(S,R’)–6 -115.775 -137.567 4.00 
(S,S’)–6 -116.702 -133.483 4.25 
7. - H
R-7 -126.213 -125.704 4.98 
S-7 -129.826 -130.033 4.69 
52. - CH2CH3 
(R,R’)–52 -136.285 -143.213 5.895 
(R,S’)–52 -128.343 -139.423 5.24 
53. - CH3 
(R,R’)–53 -142.296 -149.06 6.393 
(R,S’)–53 -139.033 -142.101 6.293 
54. - CH3 
(R,R’)–54 -144.031 -138.066 6.556 
(R,S’)–54 -138.132 -138.806 6.498 
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class A of G-protein-coupled receptors (GPCRs) family and is
one of the best characterized in terms of molecular structure
and function [7]. In recent years a series of crystal structures of
β2-AR were obtained. At first, the human β2-AR was crys-
tallized in complex with an inverse agonist, (S )-carazolol
(PDB ID: 2RH1) [8]. This structure was followed by the
reports of the β2-AR co-crystallized with other inverse ago-
nists or antagonists including alprenolol and ICI-118,551 [10]
or timolol [9]. All these structures reveal conserved mode of
binding of antagonist and inverse agonists and are thought to
represent the inactive state of the receptor. β2-AR co-
crystalized in the complex with covalently bound irreversible
agonist resulted in a structure showing significant similarities
to an inactive conformation stabilized by an antagonist. An
important breakthrough in the understanding of receptor acti-
vation was accomplished with the report by Rasmussen et al.
[11] with the use of a camelid Nb80 nanobody mimicking G-
protein interactions with the intracellular interface of β2-AR
and crystallization of the receptor in significantly altered
conformation (PDB ID: 3P0G). This structure shows outward
movement (∼11 Å) of the cytoplasmic end of the sixth trans-
membrane domain (TM VI) and rearrangement of TM Vand
TM VII. Moreover, this structure of β2-AR highly re-
sembles the one reported for opsin, an active form of a
rhodopsin [11]. The latest crystal structure of β2-AR
crystallized in the complex with Gs protein provides
insights into the process of agonist binding and receptor
activation process [12].
In the current work, the two crystal models of β2-AR were
employed to investigate molecular interactions between β2-
AR and fenoterol analogues. Molecules of fenoterol and its
derivatives, in all possible stereochemical configurations (94
structures, Table 1) were docked to the receptor into two
forms: (i) a high resolution structure of carazolol-bound re-
ceptor (an inactive form of β2-AR, In_β2-AR, PDB: 2RH1)
and (ii) a structure stabilized with Nb80 nanobody (an active
form ofβ2-AR; Ac_β2-AR, PDB: 3P0G). The structure ofβ2-
AR co-crystalized with Nb80 nanobody was selected because
no significant changes in the binding pocket were observed in
comparison with the most recent one structure (PDB ID:
3SN6). In addition, both these structures represent β2-AR
co-crystalized with the same agonist molecule, BI-167107
and the ligand location and conformation is nearly the same.
Furthermore, the use of the 3SN6-based structure is hindered
as it shows missing residues from second extracellular loop:
Ala176, Thr177, His178. Moreover, some residues creating
receptor binding pocket have missing atoms (or even whole
side chains: Asp192, Phe193, Phe194, Thr195) [12].
Our main goal was to investigate the structural aspects of
the β2-AR-fenoterol derivative complexes with the particular
emphasis put on the stereoselective effects of binding. Four
stereoisomers of fenoterol and some of its derivatives were
used as a molecular probe to identify differences in stereo-
recognition of structurally similar agonists. Moreover, we
interpreted the molecular modeling results in terms of the
binding affinities of studied compounds determined in
[3H]CGP-12177 displacement experiments reported earlier
[1, 4]. To address this, a series of docking studies followed
by molecular dynamics (MD) simulations were carried out.
MD studies were restricted to two stereoisomers of fenoterol
(compound 1) ((R ,R’)-1 and (S ,S’)-1, respectively) and aimed
at providing additional insights into stereochemical aspects of
1 bound to β2-AR.
Methods
Docking methodology
The molecules of fenoterol derivatives and their stereoisomers
presented in Table 1 were prepared using HyperChem 6.03
(HyperCube Inc., Gainesville, FL) by using Model Build
procedure and optimized using the AM1 method. Ligands
were protonated according to the physiologal pH. Their pos-
itive charge (+1) was manually added in Molegro Virtual
Docker software (MVD v. 2010.4.0.0) employed for docking
procedures [14]. The flexible, optimized ligands were docked
into the binding pocket of two high resolution X-ray crystal
structures of β2-AR (PDB IDs: 2RH1 and 3P0G). Receptor
models were prepared according to the procedure described in
the Modeling β2 adrenergic receptors section. The receptor
structures were edited in order to remove ligands and other
non-protein molecules. The procedure of docking was
performed using the binding cavity within the sphere of a
radius 11 Å, covering the ligands originally co-crystallized
with β2-AR ((S )-carazolol and BI-167107) and the closest
residues, e.g., Asp113, Ser203, Ser204, Ser207, Asn293,
Asn312, Tyr308 and Cys191, Asp192, Phe193 [8, 11,
Fig. 1 The structures of fenoterol stereoisomers (compound 1) and the
molecular template representing the fenoterol derivatives
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15–22]. The MolDock SE search algorithm was used, and the
number of searching runs was set to 100. The following
parameters were set during docking simulation: population
size = 50, maximum iteration = 1500, energy threshold =
100.00, max steps = 300, the maximum number of poses to
generate was increased to 10 from a default value of 5. The
estimation of the ligand-protein interactions was described by
the MVD implemented scoring function (MolDock Score)
[23]. The predicted positions of the ligands in the β2-AR
cavity were characterized by a simultaneous lowering of the
scoring function values; this corresponds to the high values of
the ligand binding energy. The docking algorithmwas initially
validatedwith docking simulations of the molecules originally
co-crystallized with these models (the (S )- and (R)-carazolol
molecules were docked to In_β2-AR and agonist BI-167107
was docked to Ac_β2-AR).
Molecular dynamics
Modeling β2 adrenergic receptors
Modeling of the complete structure of β2-AR in its inactive
and active states was done on the basis of the crystal structure
of human β2-AR-T4 lysozyme fusion protein with bound (S)-
carazolol [8] and the structure of a nanobody-stabilized active
state of the β2-AR with the bound full agonist BI-167107 [11],
respectively. Conformations of N-/C- termini and second in-
tracellular loop connecting TM Vand TM VI, not seen in the
crystal structures, were predicted using the ab initio approach.
The humanβ2-AR amino acid sequencewas obtained from the
Swiss-Prot database (code P07550). Modeling of N- and C-
terminal domains of the receptor (residues Met1 to Glu30 and
Cys341 to Leu413 respectively) was conducted using I-
TASSER server [23–27]. The structure of the longest second
intercellular loop of the receptor (residues Leu230 to Leu266)
was predicted using CABS program [28]. The rest of the
receptor structure was assumed to be rigid and provided re-
straints for the modeled loop. The resulting structure was
refined by applying a simulated annealing routine implemented
in GROMACS (v. 3.3) [29]. The partial atomics charges for all
receptor protein atoms used during MD calculations, were
assigned applying PDB2GMX procedure available from
GROMACS (v. 3.3) program package [29]. The total atomic
charge of the receptor protein was +2. Charges were assigned
to be in agreement with the parameterization of modified
GROMOS96 force field [32].
Simulating β2 adrenergic receptor models in the membrane
Two β2-AR models (In_β2-AR and Ac_β2-AR model) were
inserted into equilibrated palmitoyl-oleoyl-phosphatidylcholine
(POPC) cell membrane model applying Inflategro procedure
[30]. Models of β2-AR embedded in POPC lipid bilayer were
solvated with water molecules and ions were added. Two
systems under consideration consisted of receptor protein,
125 POPC lipid molecules, 16271 water molecules (including
16 water molecules seen in the β2-AR crystal structure; PDB
ID: 2RH1 in the case of In_β2-AR model) and two sodium
ions. Energy minimization was conducted applying 2000 steps
of steepest decent algorithm followed by 2000 steps of l-bfgs
algorithm. Then, the four step molecular dynamics (MD) sim-
ulation was performed. At first step each system was simulated
for 100 ps with no pressure coupling and all the protein atoms
were constrained to its initial positions with the “freeze” option.
Second step included MD simulation lasting 1 ns with position
restraints imposed on all backbone atoms of the receptor model
and Berendsen method [31] for pressure coupling. During the
third step of MD simulations, lasting 2 ns, position restraints
were removed from N- and C-terminal domain of the β2-AR
model and from loops connecting seven trans-membrane heli-
ces. Finally, production run was performed lasting 40 ns with
no restraints. All MD simulations were conducted using mod-
ified GROMOS96 force field (ffG53a6 parameters set) [32]
with additional parameters for POPC molecules taken from
Kukol [33]. SPC water model [34] was used and the PME
method [35] was applied for treatment of the long-range elec-
trostatic interactions. All bonds with hydrogen atoms were
constrained by the LINCS algorithm [36]. MD was performed
at the temperature of 310 K, pressure of 1013 hPa, and simu-
lation time step was 1 fs. All calculations and data analysis were
conducted using GROMACS (v. 3.3) program [29]. For com-
parison, MD simulation of the crystal structure of a human β2-
AR T4 lysozyme fusion protein bound to the partial inverse
agonist (S)-carazolol [8] was also preformed according to the
previously described simulation scheme.
Modeling of the ligand-receptor complexes
The PRODRG server [37] was used to obtain ligand structures
((R ,R’)- and (S ,S’)-fenoterol) and force field parameters for
MD simulation. Geometry optimization of two ligands in their
protonated-nitrogen forms was completed using Hartree–Fock
procedure employing the 6–31G* basis set in Gaussian (v.03
rev. C.02, Gaussian Inc.) [38]. Partial charges for two mole-
cules were obtained using R.E.D.III procedure [39]. The
ligand-receptor complexes were built based on the low-
energy structures obtained during the docking simulations.
Ligands were inserted in the middle of the binding sites of
In_β2-AR model and Ac_β2-AR model to preserve the inter-
action between Asp113 and the protonated amine nitrogen of
the ligands (i.e. the two meta-OH groups located at the 3,5-
dihydroxyphenyl moiety positioned in direction of TM Vand
the 3,5-dihydroxyphenyl group located in the vicinity of loop
covering receptor binding site, connecting TM IVand TM V).
The similar starting structures of all four receptor-ligand com-
plexes were generated during restrainedMD simulation lasting
4922 J Mol Model (2013) 19:4919–4930
200 ps. At that point, protein backbone atoms were
constrained to its initial positions using “freeze” option and
weak harmonic distance restraints (applying the force constant
1000 kJ mol-1 nm-1 and the distance parameters: r0=0.0 nm,
r1=0.3 nm and r2=0.5 nm) were imposed on three receptor-
ligand atom pairs (pair 1: oxygen atom of hydroxyl group of
Ser203 and the oxygen atom of the first meta -OH group of
3,5-dihydroxyphenyl moiety; pair 2: the oxygen atom of
hydroxyl group of Ser207 and the oxygen atom of the second
meta-OH group of 3,5-dihydroxyphenyl moiety; pair 3: Cγ
atom of Asp113 and the protonated nitrogen atom of the
ligand) in order to preserve similar starting position of two
ligands inside the binding cavity. Finally, two step MD simu-
lation of the receptor-ligand complexes was preformed. Dur-
ing the first step, lasting 2 ns, weak harmonic position re-
straints were imposed on backbone atoms of trans-membrane
helices of the receptor only and ligand-receptor restraints were
released. Next, second step included 5 ns production run with
no restraints. Described two step MD simulation scheme was
repeated 44 times applying random starting velocities for
every atom, 11 times for the In_β2-AR-(S ,S’)-fenoterol com-
plex, 11 times for the In_β2-AR-(R ,R’)-fenoterol complex, 11
times for the Ac_β2-AR-(S ,S’ )-fenoterol complex and 11
times for the Ac_β2-AR-(R ,R’ )-fenoterol complex, respec-
tively. Simulation parameters were identical to those used
previously during MD simulations of the β2-AR models.
Results and discussion
Ligand binding sites found by docking simulations using
the active and inactive β2-AR model
The interactions of the β2-AR and its ligands are well defined
as the receptor was co-crystallized with a series of ligands
including an inverse agonist, (S )-carazolol and an agonist, BI-
167107. All docked molecules were located according to the
similar pattern in the binding cavity in comparison to the
positions of (S )-carazolol and BI-167107 in the crystal β2-
AR structures (Fig. 2). The results of docking simulations
clearly show the differences in the binding modes of fenoterol
interacting with the active and inactive states of β2-AR. The
main findings obtained in the docking study are summarized
in Table 1. In the case of both β2-AR models, the 3,5-
dihydroxyphenyl and amine moieties of docked ligands lie
in the orthosteric site, located between TM III, TM V, TM VI
and TM VII. The positions of all docked compounds are very
similar, especially in the orthosteric site, but the binding
modes are slightly different depending on the receptor model.
This concerns the meta-OH groups and amine moiety of the
ligands mainly. The schemes of the possible interaction be-
tween β2-AR and fenoterol derivatives are shown in Figs. 3
and 4. Two meta -OH groups of the 3,5-dihyroxyphenyl
moiety of all docked compounds can create hydrogen bonds
(HBs) with Ser203 and Ser207 (TMV). Moreover, only in the
case of In_β2-AR model, one of the meta-OH group can
interact with Thr118 (TM III) (Figs. 1 and 3). The latter type
of interactions is not observed in the case of Ac_β2-AR
model. This is probably caused by slight translation of ligands
toward Asn312 (TM VII) and the second extracellular loop
(ECL2). In the case of bothβ2-ARmodels the Asp113 residue
creates the salt bridge with the positively charged amine of the
ligand. This confirms that the protonated (positively charged)
nitrogen atom of the ligand plays a significant role in binding
toβ2-AR. Additionally, β -OHmoiety of the ligand, especially
in the (R ,*’)-stereoisomers, form HB involving Asp113. The
protonated nitrogen atom and β -OH located at the chiral
center of the ligand creates HBs with Asn312 but only in the
case of Ac_β2-AR. The results obtained for fenoterol deriva-
tives suggest that simultaneous formation of HBs with serines
on TM Vand Asn312 (TM VII) is not possible in the case of
In_β2-AR, it is caused by increased distance between serines
on the 5th domain and Asn312 (∼2 Å). Nevertheless, for
Ac_β2-AR model, tilting of TM V toward the center of the
receptor causes a more intensive polar receptor-ligand inter-
actions for all fenoterol analogues, by enabling optimal en-
gagement of agonists with two experimentally identified an-
chor sites, formed byAsp113/Asn312 and Ser203/Ser207 side
chains (Fig. 4). The part of the ligand molecule containing
methyl moiety located at the α’ carbon atom of the compound
(the second chiral center) and phenyl/naphthyl rings is located
in the extension of the orthosteric site. In the case of In_β2-AR
model the 4'-hydroxy-/4'-methoxy-/4'-amino-phenyl and
methoxynaphthyl/naphthyl moieties of fenoterol derivatives
can potentially assume three possible positions in an extension
of the orthosteric site (Fig. 3). The 4'-OH, 4'-NH2 and 4'-
OCH3 groups of the fenoterol derivatives can create HB with
Cys191 or Asp192 (ECL2) (IIA site) or Thr110 (TM III) (IIB
site) or Tyr308 (TM VII) (IIC site). Furthermore, the ligand
positions are stabilized by a favorable edge-to-face interaction
with Phe193 residue (ECL2). It is depicted in Fig. 3. The
schemes of the possible interactions created between β2-AR
in its inactive (Fig. 3) and active (Fig. 4) state with fenoterol
derivatives were presented below.
The amine and β -OH moieties of (R ,R’ )-1 docked to the
Ac_β2-AR model are trapped in the network of HBs involv-
ing Asp113 and Asn312. Two meta -OH groups of ligand
form HBs with Ser203 and Ser207 of TM V (the orthosteric
site), Fig. 4. The additional hydrogen bond was formed be-
tween 4'-OH moiety of (R ,R’)-1 and residues of the second
extracellular loop (ECL2) (Cys191 or Asp192) creating the
IIA site or residues of TM VII creating the IIB site: Lys305,
Tyr308 or Trp313 (Fig. 4). The lowest scoring function values
were obtained for positions in which 4'-OH moiety of the
ligand creates HB with Lys305 (TM VII) or Cys191
(ECL2). Thus, (R ,R’ )-1 forms a very similar pattern of
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interactions as BI-167107 molecule co-crystallized originally
with β2-AR (Ac_β2-AR model) (Fig. 2b). In the (R ,R’ )-1-
In_β2-AR complex two meta-OH moieties form HBs with
Ser203 (TM V) (seldom with Ser207) and Thr118 (TM III).
The amine and β -OH moieties of the ligand form HBs with
Asp113 (TM III) (Fig. 3). In this case Asn312 is too distant to
interact with the amine or β -OH group of the ligand; similarly,
due to the reorientation of Lys305 in the In_β2-AR model, no
direct interaction between this residue and the ligand 4'-OH
moiety was observed. In the case of In_β2-AR model, the 4'-
OH moiety interacts with Tyr308 (TM VII) by hydrogen
bonding mainly. Note than the abovementioned residue,
Tyr308, plays an important role in the selective binding of
the agonists toβ2-ARwith respect toβ1-AR [41]. The oxygen
atom of the phenolic group of the ligand seems to interact
preferentially with the hydroxyl group of the Tyr308 residue
[42]; its interactions with Cys191 and Asp192 (ECL2) are also
possible. Comparison of MolDock Score functions character-
izing the two complexes including (R ,R’ )-1 suggests that the
complex formed with Ac_β2-AR should be more stable;
the difference between MolDock Score values (Table 1)
is -4.5 kJ mol-1.
The analysis of the β2-AR molecular models reveals that
Tyr308 is neighbored by several other aromatic residues (e.g.,
Trp109, Phe193, Trp286, Phe289, Phe290, His296 or Tyr316)
and the aminoaryl moiety of the fenoterol analogues can form
a network of π−π interactions within this region of β2-AR.
Especially, the naphthyl moiety with increased π electron
density can interact strong enough to overcome the lack of
the hydrogen bond acceptor effect in (R ,R’ )-5. We observed
that the number of aromatic rings influences the scoring
function values. For compounds with the naphthyl moiety
(compounds: 5 and 53) MolDock Score values are smaller
than that for compound with the phenyl ring (compound 3).
Moreover, compounds containing naphthyl moieties are char-
acterized by higher pKi values in comparison to the com-
pound with phenyl ring (Table 1). The naphthyl moiety can
create π−π interactions with several aromatic residues distrib-
uted in the binding region instead of one preferential direction,
characteristic of (R ,R’)-1 or (R ,R’)-2 donating their oxygen
Fig. 2 The comparison of the positions of ligands co-crystallized with
β2-AR (gray), (S)-carazolol (PDB ID: 2RH1) (a) and BI-167107 (PDB
ID: 3P0G) (b) with (R ,R’)-1 docked to In_β2-AR (a) and Ac_β2-AR
model (b). The positions of both aromatic rings of (R ,R’)-1 are very
similar to those of (S)-carazolol and BI-167107 present in the crystal
structures of β2-AR. Positions of (R ,R’)-1, characterized by the lowest
scoring function values are presented.
Fig. 3 The scheme of the
possible interactions in the
(R ,R’)-1-In_β2-AR complex.
Red and green lines denote
hydrogen bonds and hydrophobic
interactions ( Π-Π interactions),
respectively. The selected amino
acid residues are presented in the
1-letter code [40]
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atoms for HB interaction with Tyr308. In several cases, the
naphthyl moieties of the studied ligands take the same position
as aromatic rings of carazolol bound to the In_β2-AR struc-
ture (Fig. 2a) in which a carbazole heterocycle ring of
carazolol forms a network of π−π interactions with Phe289,
Phe290 and Phe193 [8]. Docking results show that com-
pounds containing the naphthyl group, contrary to compounds
with phenyl moiety, are more likely to interact with the other
aromatic residues by π−π stacking. This type of interaction is
not preferred in the case of derivatives with the phenolic
moiety; their rings are directed rather toward Tyr308 or resi-
dues located on ECL2 (Cys191 or Asp192) but with no
significant π−π interactions.
Docking simulations: stereoselective binding of fenoterol
derivatives to β2-AR
Experimental binding affinities determined for the studied
compounds suggest that the stereochemistry plays a crucial
role in the interactions with the receptor [1, 4–6]. Thus, it is
very important to describe how docking simulations explain the
stereoselective nature of ligand-receptor interactions. Figure 5
presents the binding modes of the (S ,S’)-1 molecule to In_β2-
AR and Ac_β2-AR, respectively. Docking of (S ,S’)-1 to the
In_β2-AR model reveals that the position of the molecule’s
backbone is virtually the same as in (R ,R’)-1 docked to the
In_β2-AR model. The only difference lies in the reorientation
of moieties associated with the two chiral centers, β-OH and –
CH3 groups, which are in the opposite direction when compar-
ing with (R ,R’)-1-In_β2-AR complex, Fig. 5a. As a result, the
β-OH moiety of (S ,S’)-1 does not form a HB with Asp113 of
In_β2-AR and the methyl moiety does not exhibit favorable
orientation toward hydrophobic surface of the binding site
formed by TM III (Trp109) and ECL2 (Phe193). The inverted
positions of two moieties in (S ,S’)-1-In_β2-AR complex result
in significant increase of theMolDock Score value with respect
to the (R ,R’)-1-In_β2-AR complex; the difference is 9.0 kJ
mol-1 (Table 1). This value reflects the difference in pKi values
determined experimentally for (R ,R’)-1 and (S ,S’)-1 (ΔpKi =
1.9, Table 1). Docking of (S ,S’)-1 to Ac_β2-AR reveals more
significant differences in the interactions pattern with respect to
the (R ,R’)-1-Ac_β2-AR complex. The aminoalkyl part of the
(S ,S’)-1 molecule is oriented in almost the same manner within
the binding site as the corresponding part of the (R ,R’)-1, 4'-
OH moiety interacts via HB with Lys305 and both amine and
β-OH groups form a network of hydrogen bonds with Asp113
Fig. 4 The scheme of the
possible interactions in the
(R ,R’)-1-Ac_β2-AR complex.
Red and green lines denote
hydrogen bonds and hydrophobic
interactions (Π-Π interactions),
respectively. The selected amino
acid residues are presented in the
1-letter code [40]
Fig. 5 The structural models of
the (S ,S’)-fenoterol-In_β2-AR
(a) and the (S ,S’)-fenoterol-
Ac_β2-AR complexes (b)
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and Asn312, Fig. 5b. The 3,5-dihydroxyphenol moiety of
(S ,S’)-1 is significantly reoriented that only one meta-OH
moiety is able to form HB with Ser203. Moreover, β -OH
moiety of (S ,S’)-1 does not form HB with Asp113 of Ac_β2-
AR. Similarly, the S’ configuration forces the methyl moiety
associated with the second chiral center to reorient and point
away from the surface of the TM III (Trp109), Fig. 6. Surpris-
ingly, these significant differences between (R ,R’)-1-Ac_β2-
AR and (S ,S’)-1-Ac_β2-AR complexes are not translated into
notable differences in MolDock Score values, equal to -133.5
and -134.6 kJ mol-1, respectively (Table 1). Docking results
show a good correlation with the binding affinities (pKi values)
of the fenoterol derivatives. The In_β2-AR model predicts the
stereoselective binding effects better than the Ac_β2-AR
model, Tab. S1, Figs. S1, S2. This results from the
better correlation of scoring function values with pKis
determined using β2 selective antagonist, [
3H]CGP-
12117, in a radioligand displacement study [1, 4]. Thus,
the experimental pKi values reflect the inactive state of
receptor rather than the active one. Moreover, the ap-
plied docking procedure appeared not to be sensitive
enough to differentiate between binding affinities of
stereoisomers of the same compound (Table 1).
Docking simulations: influence of the R1 and R2 substituents
on the binding to β2-AR
Figures 6 and 7 show the differences of the docking results of
the two selected fenoterol derivatives, namely (R ,R’)-52 and
(R ,R’ )-54 (Table 1) compared to the binding modes of
fenoterol to inactive and active form of the receptor
(Fig. 5a, b). The replacement methyl moiety for the ethyl
group attached to the second chiral center (R1 substituent,
Fig. 1) causes the reorientation of the 4'-hydroxyphenyl moi-
ety of the (R ,R’)-52 in the complex with Ac_β2-AR in com-
parison to the (R ,R’)-1-Ac_β2-AR complex. The ethyl group
causes the shift of the 4'-hydroxyphenyl moiety away from
Lys305 and therefore lack of HB with this residue. All other
interactions are analogous to those present in the (R ,R’ )-1-
Ac_β2-AR complex, Fig. 4. The (R ,R’)-52-In_β2-AR com-
plex shown in Fig. 6a reveals a very similar pattern of the
ligand-receptor interactions as that found in (R ,R’ )-1-In_β2-
AR complex (Fig. 3). The (R ,R’)-54 molecule contains 4’-
methoxy-1-naphthyl moiety at the aminoalkyl tail (R2 substit-
uent). This modification does not produce very significant
changes in the position of the molecule within the Ac_β2-
AR binding site in comparison to that of fenoterol. All the
principal interactions observed for the (R ,R’ )-54-Ac_β2-AR
complex are still present, Fig. 7. More significant differences
can be noticed for (R ,R’ )-54 docked to In_β2-AR. In this case,
the ligand molecule is reoriented to prevent the β -OH group
from creating a HB with Asp113 and bulky 4-methoxy-1-
naphthyl moiety is pushed into the center of the binding site
due to the interaction with Tyr308. Both (R ,R ’)-52 and
(R ,R’)-54 showed qualitatively different behavior in a func-
tional test in comparison to the compounds like (R ,R ’)-1 or
(R ,R’)-2. (R ,R’)-52 , having an ethyl moiety attached to the
second chiral center, has a significantly weaker binding affin-
ity relative to (R ,R ’)-1 (1,273 nM versus 345 nM) when
[3H]CGP-12177 is the marker ligand, is active in the cAMP
accumulation assay but is not active in the cardiomyocyte
contractility test [4]. Interestingly, (R ,R ’)-54, which contains
the 4’-methoxy-1-naphthyl moiety, is not active in the cAMP
accumulation assay, but this stereoisomer is the most potent
derivative, appeared to have very low Ki value determined
experimentally using the radioactive antagonist [3H]CGP-
12177 and the exceptional subtype selectivity (the Kiβ1/
Kiβ2 ratio=578). This compound was further characterized
in the cardiomyocyte contractility assay and its EC50 value
was 3 nM which place this compound among the strongest
selective agonists of the β2-AR ever described [4]. The
obtained results confirm the influence of R1 and R2 substitu-
ents in the fenoterol molecule (Fig. 1) on its binding toβ2-AR.
This is in agreement with the experimentally determined pKi
values for stereoisomers of fenoterol and its derivatives [1, 4].
Considering the R2 substituent in the template molecule
(Fig. 1), the pKi values corresponding to the fenoterol deriv-
atives exhibit the following trend: 4'-OH>4'-OCH3>4'-NH2.
The above trend holds also in the case of compounds contain-
ing either phenyl or naphthyl group in R2. Furthermore, the
compounds containing the naphthyl rings in the R2 substitu-
ents exhibit larger affinity for β2-AR in comparison to the
corresponding ligands with phenyl ring in R2 (Table S2)
[unpublished data].
Fig. 6 Structural models of the
(R ,R’)-52-In_β2-AR complex (a)
and the (R ,R’)-52-Ac_β2-AR
complex (b)
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MD simulations: binding modes of two fenoterol isomers
The radioligand binding studies showed that fenoterol stereo-
chemistry greatly influences the binding affinity of derivatives
to β2-AR with relative order (R ,R’)>(R ,S’)>(S ,R’)>(S ,S’) [1]
and a similar trend was found in functional assays (ligand
induced the cAMP accumulation and the cardiomyocyte con-
tractility measurements). Two models: In_β2-AR and Ac_β2-
AR were used for investigation of different binding modes of
(R ,R’)- and (S ,S’)-fenoterol isomers of 1 using MD simula-
tions. Both ligands were inserted in the middle of the receptor
binding site and 44 MD simulations were conducted. In gen-
eral, the starting positions of two fenoterol isomers inside the
binding site of In_β2-AR and Ac_β2-AR are very similar
(Online Resource 4). Two hydroxyl groups (meta-OH) of the
ligand 3,5-dihydroxyphenyl moiety are situated in a vicinity of
the Ser203 and Ser207 residues from TMV,whereas the ligand
protonated nitrogen atomwas in close distance to Asp113 (TM
III) (Fig. 3). Slightly different binding mode was observed in
the case of Ac_β2-AR-(S ,S’)-fenoterol complex (Fig. 5). The
phenolic group of the ligand was oriented toward TM VII,
whereas its hydroxyl group was directed toward extracellular
part of the receptor. During 44 MD simulations with no re-
straints (11MD simulations for each fenoterol isomer–receptor
complex, each lasting 5 ns) both fenoterol isomers adopted
different conformations inside the receptor binding sites (On-
line resource 5). Inspection of the 44 MD trajectories of the
receptor-ligand complexes revealed much higher conforma-
tional stability of the (R ,R’)-fenoterol when compared to the
(S ,S’)-fenoterol isomer, Online resource 5. The flexibility of
two ligands has been monitored in the form of RMSD auto-
correlation function. The observed averaged RMSD values are
lower for (R ,R’)-fenoterol isomer when interacting with both
In_β2-AR and Ac_β2-AR for all monitored time intervals
(Online resource 5). The calculation of root mean square
fluctuation (RMSF) parameter for position of all ligand atoms
indicated specific fragments of two fenoterol isomers showing
the highest difference in RMSD fluctuation (Fig. 8). In the case
of In_β2-AR-fenoterol complexes atoms creating the chain
connecting 3,5-dihydroxyphenyl and phenolic moieties and
atoms present in the 4’-hydroxyphenyl group of (R ,R’ )-
fenoterol display much lower averaged displacement during
the simulation. Plot presenting measured distances between
receptor-fenoterol atom pairs (Online resource 6) indicated
that those fragments include atoms (protonated amine and
4’-OH moiety) responsible for direct contact with β2-AR
binding site. Additionally, the biggest fluctuation of ligand
conformations were observed for ligand-In_β2-AR com-
plexes, Fig. 8.
The analysis of MD trajectories indicated that (R ,R’ )-
fenoterol in the complex with In_β2-AR creates a stable HB
network with residues Asp113 and Asn312 (Online resource
6). The carboxyl group of Asp113 forms close contact with
hydrogen atoms at the ligand protonated amine group and
with H16 atom of β -OH (see Fig. 8 for atom numbering).
The position of Asp113 sidechain is also stabilized by the
interaction with Tyr316 (TMVII). The nitrogen and hydrogen
atoms of the Asn312 residue form close contacts with ligands
H20 and O15 atoms, respectively. The HB between 4’-
hydroxyphenyl group of the ligands and Asp192 (ECL2)
was also well preserved during MD simulation. Two meta-
OH groups of the ligand 3,5-dihydroxyphenyl moiety were
oriented toward Ser203 and Ser207 residues from TM V, but
the distance was too large to form a contact. Analysis of the
MD simulation trajectories of Ac_β2-AR-ligand complexes
revealed that no stable connection with Ser203/207 from TM
helix V was observed. During the MD simulations two li-
gand's hydroxyl groups occasionally created hydrogen bonds
with serine residues but this event was rather rare (Fig. 6
shows the measured ligand-receptor atom pairs distances av-
eraged over 22 MD simulations). In our opinion this is due to
two main reasons: (i) fenoterol moiety containing one aromat-
ic ring with two hydroxyl groups directed toward TM helix V
occupies the same space as the much larger two ring system of
the BI-167107 agonist moiety seen in 3P0G crystal structure
which allows for higher mobility of this fenoterol fragment
inside the receptor binding site; (ii) hydroxyl group of pheno-
lic moiety of fenoterol molecule interacts with Asp192 from
second extracellular loop which favors shifting the ligand
position; this, in turn, increases the distance from TM helix
V and weakens the interaction with two Ser203/207 residues.
In addition, Asn293 residue, which is believed to play a
crucial role in stereoselective agonist binding and receptor
activation [43] did not form a stable interaction with the ligand
during MD simulation. In the contrast, the (S ,S’ )-fenoterol
isomer in complex with In_β2-AR did not maintained a stable
Fig. 7 Structural models of the
(R ,R’)-54-In_β2-AR complex (a)
and the (R ,R’)-54-Ac_β2-AR
complex (b)
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position in the receptor binding cavity. On average, only one
well preserved contact during each of 11 MD simulations was
formed between ligand protonated nitrogen atom and carbox-
yl group of the Asp113 residue. Interaction between Asn312
and the ligand involved rotation of amino acid side chain and
was frequently interrupted which is associated with high con-
formational flexibility of the (S ,S’ )-fenoterol isomer. The
average distance between 4’-hydroxyphenyl group of the
ligand and carboxyl group of Asp192 was too large (> 4 Å)
to establish a stable hydrogen bond. Ligand movement in the
binding cavity allowed two hydroxyl groups of the 3,5-
dihydroxyphenyl moiety to move closer toward Ser203 and
Ser207, but no stable connection was made. Analysis of MD
trajectories revealed that the two fenoterol isomers of 1 are
conformationally flexible and do not form common invariable
interaction pattern with Ac_β2-AR. Ionic interactions
between ligands protonated nitrogen and Asp113 and
HB between 4’-hydroxyphenyl group of the ligand and
carboxyl group of Asp192 are the most frequently ob-
served interactions, Online resource 6. A small number
of water molecules entered the receptor binding cavity
during all MD simulations but no common interaction
pattern was observed.
Conclusions
The main results of our studies can be summarized as follows:
1. All derivatives of 1 take similar positions in the binding
cavity of β2-AR, especially in the orthosteric site (Figs. 3
and 4). The meta-OH groups of tested compounds create
hydrogen bonds with serines on TM V (Ser203, Ser207).
The protonated amine of the ligands creates a salt bridge
with the Asp113 sidechain (TM III). Moreover, the β-OH
moiety of (R ,*’)-stereoisomers can form the HB with
Asp113. The remaining part of ligands, including α’ alkyl
chain (R2 substituent) and phenyl/naphthyl rings, is located
in the extension of the orthosteric site. The compounds can
be oriented in the extension of the orthosteric site according
to diverse patterns, depending on the character of the R2
substituent in the leading structure of 1 (Fig. 1) and the β2-
AR model. The observations listed above are common for
the two structural models of the receptor: inactive β2-AR
(In_β2-AR) and active β2-AR (Ac_β2-AR).
2. The comparison of In_β2-AR and Ac_β2-AR reveals
several substantial differences between binding modes
characteristic of them. Unlike Ac_β2-AR, in the case of
Fig. 8 The averaged RMSF
values of ligand atoms during 5 ns
of MD simulation of ligand-
In_β2-AR (top) and ligand-
Ac_β2-AR (bottom) complexes:
(R ,R’)-fenoterol – red, (S ,S’)-
fenoterol – black. Blue and green
rectangles represent molecule
fragment with highest difference
of RMSF values
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In_β2-AR model, only the Thr118 and Thr110 residues
interact with one meta-OH and 4’-OH groups of ligand
respectively. Docking results indicate that in the case of
Ac_β2-AR the amine group of ligand interacts also with
Asn312 (TM VII). This interaction does not exist in the
case of In_β2-AR, as the location of Asn312 is too distant.
In the In_β2-AR model ligands can take three possible
positions in the extension of the orthosteric site (IIA, IIB
and IIC site). In the case of Ac_β2-AR only two positions
in the extension of the orthosteric site were observed
(Figs. 3 and 4). The most significant difference between
fenoterol derivatives bound to In_β2-AR and to Ac_β2-
AR lies in the hydrogen bonding contacts with Lys305
(TM VII) created only in the case of Ac_β2-AR model.
3. Interestingly, docking studies reveal different binding
modes in the extension of the orthosteric site of compounds
containing naphthyl or phenyl moieties. Compounds con-
taining the 4’-hydroxy-/4’-methoxy-/4-‘amino-phenyl
group interact mainly with Cys191 or Asp192 (ECL2,
IIA site). Additionally, the interactions with Lys305 (TM
VII) in the case of Ac_β2-AR are preferred. In the case of
compounds containing the methoxynaphthyl/naphthyl
moieties, the position of these groups is usually close to
Tyr308. The naphthyl moiety of derivatives 5, 53 and 54
can form π−π interactions with aromatic ring of Tyr308
and/or several aromatic residues neighboring Tyr308. The-
se hydrophobic interactions cause the compounds 5, 53
and 54 to interact strong enough to overcome the lack of
the HB acceptor/donor effect.
4. Molecular dynamics simulations indicate that the β -OH
and (–NH2
+–) functional groups interact with Asp113 and
Asn312. These interactions are more stable in the case of
the receptor active state (Ac_β2-AR) than in the inactive
one (In_β2-AR). The distances between the protonated
amine of ligands and both Asp113 and Asn312 residues
are larger for In_β2-AR. It causes the β -OH moiety of
(R ,R’ )-fenoterol to lose HB with Asn312. In comparison
to the docking results, MD simulations do not reveal the
presence of HBs between Ser203/Ser207 and meta -OH
moieties of ligands (Online resource 6). During the MD
simulations ligand drifts away from TM Vand looses the
possibility of direct interaction with the serine residues.
The indirect interaction is possible, though, according to
the scenario water molecules form the ‘bridges’ between
the meta-OH moiety (ligand) and Ser203/Ser207.
5. The results obtained by us are in accordance with the
experimental data and indicate that the most potent com-
pounds are those with (R ,*’)-configuration. Docking
studies indicate that the hydroxyl group at the first chiral
center of ligand creates HB with Asp113 or/and Asn312
in the case of (R ,*’)-stereoisomers mainly. Further, mo-
lecular dynamics simulations confirm the existence of the
stereoselective effects accompanying the ligand-receptor
interactions; namely, different stereoisomers exhibit di-
verse conformational behaviors and distances between
characteristic ligand-receptor atom-atom pairs, Fig. S6.
6. Molecular dynamics simulations reveal that the available
conformational phase space is larger in the case of (S ,S’)-
fenoterol while in the case of (R ,R’)-fenoterol it is signif-
icantly reduced (Online resource 5). The largest differences
between (R ,R’)- and (S ,S’)-fenoterol are observed in the
region containing the β-OH, (–NH2
+–) and 4’-OH func-
tional groups, which interact with the receptor (Fig. 8).
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